RedHill Biopharma (RDHL) Receivables - Net (2016 - 2025)

RedHill Biopharma (RDHL) has reported Receivables - Net for 10 consecutive years, with $5.4 million the latest figure, recorded in Q2 2025.

• On a quarterly basis, Receivables - Net rose 449.28% year-over-year to $5.4 million in Q2 2025; TTM through Jun 2025 was $5.4 million, a 449.28% increase from a year earlier, with the FY2025 full-year figure at $79000.0, down 96.89% from the prior year.
• Receivables - Net was $5.4 million for Q2 2025 at RedHill Biopharma, up from $2.5 million in the prior quarter.
• Over five years, Receivables - Net peaked at $36.0 million in Q3 2022 and troughed at $974000.0 in Q2 2024.
• A 5-year average of $19.0 million and a median of $24.6 million in 2021 frame the typical range for Receivables - Net.
• Across the five-year window, Receivables - Net jumped 1257.37% in 2021 and sank 92.49% in 2023, its largest moves.
• Over 5 years, Receivables - Net stood at $31.7 million in 2021, then advanced by 8.98% to $34.5 million in 2022, then slumped by 92.49% to $2.6 million in 2023, then declined by 2.01% to $2.5 million in 2024, then jumped by 110.71% to $5.4 million in 2025.
• The last three Receivables - Net figures came in at $5.4 million (Q2 2025), $2.5 million (Q4 2024), and $974000.0 (Q2 2024), per Business Quant data.